Recombinant Human IGF-BP1 (Carrier-free)
| Cat No. | Size | Price | Quantity | |
|---|---|---|---|---|
| 21-7066-U005 | 5 µg | $76.00 | ||
| 21-7066-U025 | 25 µg | $175.00 | ||
| 21-7066-U100 | 100 µg | $585.00 | ||
| 21-7066-U500 | 500 µg | $1,795.00 |
Lead time: 2-3 business days
Technical Data Sheet
Request Custom/BulkDescription
Insulin-like growth factor binding proteins (IGF-BPs) are a family of secreted proteins with conserved amino- and carboxy-terminal sequences and variable mid-regions. IGF-BPs control the distribution, function and activity of ≥≥IGFs in various cell tissues and body fluids. IGF-BP1 is expressed in serum, liver, decidua, kidneys and amniotic fluid, and binds to IGFs I and II. Phosphorylated IGF-BP1 hinders IGF actions, whereas nonphosphorylated IGF-BP1 is stimulatory. Insulin and corticosteroids affect hepatocyte production of IGF-BP1.
Insulin-like growth factor binding proteins (IGF-BPs) are a family of secreted proteins with conserved amino- and carboxy-terminal sequences and variable mid-regions. IGF-BPs control the distribution, function and activity of ≥≥IGFs in various cell tissues and body fluids. IGF-BP1 is expressed in serum, liver, decidua, kidneys and amniotic fluid, and binds to IGFs I and II. Phosphorylated IGF-BP1 hinders IGF actions, whereas nonphosphorylated IGF-BP1 is stimulatory. Insulin and corticosteroids affect hepatocyte production of IGF-BP1.
Hide
Product Details
| Name | Recombinant Human IGF-BP1 (Carrier-free) |
|---|---|
| Cat. No. | 21-7066 |
| Alternative Names | Insulin-like Growth Factor-Binding Protein 1, IBP-1, Placenta Protein 12 (PP12) |
| Amino Acid Sequence | MAPWQCAPCS AEKLALCPPV SASCSEVTRS AGCGCCPMCA LPLGAACGVA TARCARGLSC RALPGEQQPL HALTRGQGAC VQESDASAPH AAEAGSPESP ESTEITEEEL LDNFHLMAPS EEDHSILWDA ISTYDGSKAL HVTNIKKWKE PCRIELYRVV ESLAKAQETS GEEISKFYLP NCNKNGFYHS RQCETSMDGE AGLCWCVYPW NGKRIPGSPE IRGDPNCQIY FN |
| Authenticity | Verified by N-terminal and Mass Spectrometry analyses (when applicable). |
| Bioactivity | The ED50 was determined by its ability to inhibit IGF-I induced proliferation of MCF-7 is ≤ 0.5 µg/ml in the presence of 6 ng/ml of human IGF-I. |
| Endotoxin Level | Endotoxin level is <0.1 ng/μg of protein (<1 EU/μg). |
| Molecular Mass | Recombinant human IGF-BP1 is a 25.4 kDa protein consisting of ≥ 235 amino acid residues (Isoform A). |
| Protein Content | Content Verified by UV Spectroscopy and/or SDS-PAGE gel. |
| Purity (%) | 98 |
| Source | E. coli |
| Reactivity | Human |
| Research Areas | Apoptosis; Cancer; Diabetes / Weight Regulation; Proliferation |
| Reconstitution | See Certificate of Analysis (COA) for lot specific reconstitution information. |
| Application | Bioassay |
Application Key:
FC = Flow Cytometry; FA = Functional Assays; ELISA = Enzyme-Linked Immunosorbent Assay; ICC = Immunocytochemistry; IF = Immunofluorescence Microscopy; IHC = Immunohistochemistry; IHC-F = Immunohistochemistry, Frozen Tissue; IHC-P = Immunohistochemistry, Paraffin-Embedded Tissue; IP = Immunoprecipitation; WB = Western Blot; EM = Electron Microscopy
*Tonbo Biosciences tests all antibodies by flow cytometry. Citations are provided as a resource for additional applications that have not been validated by Tonbo Biosciences. Please choose the appropriate format for each application and consult the Materials and Methods section for additional details about the use of any product in these publications.